Companies · Software / Tech
Boston · Software / Tech · refined from filed group “Other Health Care”
Diligence memoA one-page analyst read on Amplitude Vascular Systems, Inc. — recommendation, valuation, rhythm, risks.→Amplitude Vascular Systems, Inc. looks fair against its niche peers and is quiet on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the technology sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Amplitude Vascular Systems, Inc. is one of 3920 Software / Tech companies tracked from Boston. By capital raised it ranks in the upper tier (ahead of 85% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 75%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the technology sector profile. Directional, not a quoted figure.
Benchmarked against 3920 companies in Software / Tech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 85% of sector peers (real $). Modeled value above 80% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #114 of 174.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Argyle Systems Inc. | Series B | $36.7M | $596.4M | 2.91× |
| Shoreline Software, Inc. | Series B | $57.0M | $584.7M | 2.85× |
| ALICE Technologies, Inc. | Series B | $59.6M | $545.1M | 2.66× |
| Tint Technologies Inc. | Series B | $29.6M | $528.5M | 2.58× |
| Vanilla Technologies Inc. | Series B | $49.3M | $496.8M | 2.42× |
| Red Team Software, LLC | Series B | $28.3M | $494.6M | 2.41× |
| LongPath Technologies, Inc. | Series B | $39.8M | $488.8M | 2.38× |
| SmartX Technology Solutions Inc. | Series B | $42.0M | $488.6M | 2.38× |
| On Demand Technologies, Inc. | Series B | $54.9M | $442.0M | 2.15× |
| Meow Technologies Inc. | Series B | $28.1M | $440.3M | 2.15× |
| Paytient Technologies, Inc. | Series B | $53.9M | $436.9M | 2.13× |
| Trunk Technologies, Inc. | Series B | $28.5M | $429.9M | 2.10× |
| Amplitude Vascular Systems, Inc. this company | Series B | $29.3M | $159.7M | 0.78× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $1.2M | 2020-06-25 | $6.2M | $42.2M | 90% |
| Series A | $4.4M | 2022-10-17 | $20.0M | $48.3M | 90% |
| Series B | $23.6M | 2024-10-15 | $131.4M | $159.7M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| David Long | — | 4 other | 2020-06 |
| Louis Cannon | — | 2 other | 2020-06 |
| Mark Toland | — | 1 other | 2020-06 |
| William H. Kucheman | — | 1 other | 2024-10 |
| Andrew H. Casey | — | — | 2024-10 |
| Hank Kucheman | — | — | 2022-10 |
| Hitinder Gurm | — | — | 2020-06 |
| Jason H. Richardson | — | — | 2024-10 |
| Robert Chisena | — | — | 2020-06 |
| Sean H. Gilligan | — | — | 2024-10 |
Amplitude Vascular Systems, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Animal Microbiome Analytics, Inc. | Software / Tech | Series B | $29.3M | $109.8M | same sector · same stage |
| H3X Technologies Inc. | Software / Tech | Series B | $29.4M | $170.5M | same sector · same stage |
| Savant Labs, Inc. | Software / Tech | Series B | $28.8M | $118.4M | same sector · same stage |
| Logik.io Inc. | Software / Tech | Series B | $28.5M | $177.6M | same sector · same stage |
| Reveal Technology, Inc. | Software / Tech | Series B | $28.5M | $159.8M | same sector · same stage |
| Buzzer Technologies Inc. | Software / Tech | Series B | $28.4M | $132.2M | same sector · same stage |
| Cultivation Technologies, Inc. | Software / Tech | Series B | $28.0M | $152.3M | same sector · same stage |
| Big Watt Digital LLC | Software / Tech | Series B | $30.7M | $135.3M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Attwill Vascular Technologies LP | Software / Tech | Seed | $29.6M | 80% |
| NeuroVasc Technologies, Inc. | Software / Tech | Series A | $115.4M | 80% |
| Advanced Interactive Response Systems, LLC | Software / Tech | Pre-Seed | $22.0M | 77% |
| EBR Systems, Inc. | Software / Tech | Series C | $203.3M | 77% |
| Vigor Medical Systems, Inc. | Healthtech | Pre-Seed | $20.3M | 77% |
| Accuity Delivery Systems, LLC | Software / Tech | Series B | $776.6M | 77% |
| Tuned Care, Inc. | Healthtech | Pre-Seed | $3.5M | 77% |
| Swift Health Systems Inc. | Healthtech | Series D+ | $2.0B | 77% |
See where Amplitude Vascular Systems, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Amplitude Vascular Systems, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.